Compare Sana Biotechnology Inc (SANA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard S&P 500 ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Vanguard S&P 500 ETF trades at $687.43. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VOO | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $698.29 |
52-Week Low | $2.68 | $571.45 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
VOO trades at $682.20, down 0.14% with a bearish technical signal from moving averages. The ETF shows neutral momentum indicators with RSI at 51.60, while support levels cluster around $677-681. Recent news highlights S&P 500 concentration risks and ongoing debates about market valuation levels amid tech dominance.
The outlook remains cautious as technical weakness contrasts with long-term ETF benefits. Key risks include market concentration in tech stocks and potential valuation concerns, while the dividend yield provides income support for patient investors seeking broad market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
